These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Atypical presentation of acute neurotoxicity secondary to oxaliplatin. Uña E J Oncol Pharm Pract; 2010 Dec; 16(4):280-2. PubMed ID: 20015928 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948 [TBL] [Abstract][Full Text] [Related]
28. [A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy]. Nishigami K; Kawami H; Yamaguchi T; Yamaguchi K; Kato S Gan To Kagaku Ryoho; 2009 Oct; 36(10):1765-8. PubMed ID: 19838045 [TBL] [Abstract][Full Text] [Related]
29. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157 [TBL] [Abstract][Full Text] [Related]
30. Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis. Kobayashi M; Endo S; Hamano Y; Imanishi M; Akutsu D; Sugaya A; Ochi D; Moriwaki T; Hyodo I Intern Med; 2016; 55(2):127-30. PubMed ID: 26781010 [TBL] [Abstract][Full Text] [Related]
31. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112 [TBL] [Abstract][Full Text] [Related]
32. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran. Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769 [TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review. Forcello NP; Khubchandani S; Patel SJ; Brahaj D J Oncol Pharm Pract; 2015 Apr; 21(2):148-56. PubMed ID: 24500808 [TBL] [Abstract][Full Text] [Related]
34. Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Lim KH; Huang MJ; Lin HC; Su YW; Chang YF; Lin J; Chang MC; Hsieh RK Anticancer Drugs; 2004 Jul; 15(6):605-7. PubMed ID: 15205605 [TBL] [Abstract][Full Text] [Related]
35. Which drug combination for colorectal cancer? Doggrell SA Expert Opin Pharmacother; 2004 Dec; 5(12):2621-4. PubMed ID: 15571479 [TBL] [Abstract][Full Text] [Related]
36. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Moreau LC; Rajan R; Thirlwell MP; Alcindor T Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831 [TBL] [Abstract][Full Text] [Related]
38. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study. Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679 [TBL] [Abstract][Full Text] [Related]
39. An immediate hemolytic reaction induced by repeated administration of oxaliplatin. Chen VM; Thrift KM; Morel-Kopp MC; Jackson D; Ward CM; Flower RL Transfusion; 2004 Jun; 44(6):838-43. PubMed ID: 15157248 [TBL] [Abstract][Full Text] [Related]
40. [A case of interstitial lung diseases in patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX)]. Nakagawa M; Hamada A; Yoshihara Y; Ishizaka T; Fukushima M; Takahashi N; Sawada R; Mukai J Gan To Kagaku Ryoho; 2011 Feb; 38(2):317-20. PubMed ID: 21368504 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]